Italian ingredient company Nous has successfully secured €2.315 million in a seed funding round to advance its commercialization efforts for its innovative botanical ingredients. The investment, led by dsm-firmenich Ventures, will fuel the international expansion and further development of its flagship product, Koncentra. This science-backed ingredient is designed as a natural alternative in the growing energy, focus, and mood support category.
Strategic Investment for Commercial Expansion
The funding syndicate includes significant participation from FoodSeed, a program within CDP Venture Capital’s National Accelerator Network established with Eatable Adventures. This powerful collaboration brings together crucial strategic and financial expertise spanning ingredient innovation, foodtech commercialization, and global scale-up strategies. The investment is poised to transition Koncentra from its current clinical development phase into a widely available commercial product.
Advancing Scientific Validation and Production
A primary allocation of the new capital will be directed toward commissioning additional clinical studies to bolster the scientific evidence supporting Koncentra's functional benefits. Concurrently, Nous will use the funds to significantly expand its supply chain capabilities across both Europe and Asia to prepare for increased demand. This strategic investment in research and infrastructure is essential for solidifying its market position for the next phase of growth.
Proprietary Technology and Market Demand
Koncentra is produced using Nous's proprietary extraction platform, a technology that creates unique, science-backed botanical ingredients for the food, beverage, and nutraceutical sectors. The company is directly addressing a clear consumer shift towards natural products that effectively support energy and overall wellbeing. Its established partnership with dsm-firmenich and a growing network of commercial partners across Europe underscore the rising market interest.
Ambitious Roadmap for Global Growth
Looking ahead, Nous has outlined an ambitious roadmap for global growth, targeting a strategic entry into the United States market by November 2026. The company also aims to publish at least three comprehensive clinical studies and achieve an annual production capacity of 60 tonnes of Koncentra by the end of 2027. These clear objectives reflect the company's confidence in its product and its well-defined strategy for capturing a global audience.
Investor Confidence in a Science-Based Approach
Investor support for Nous is firmly rooted in its science-based approach and proprietary technology, a sentiment echoed by representatives from Eatable Adventures and CDP Venture Capital. Lorenzo Pessini, CEO of Nous, emphasized that the funding provides the necessary resources to strengthen Koncentra's scientific standing and develop next-generation ingredients. This shared vision highlights the company's potential to address significant challenges within the modern food and health industries.
This €2.315 million seed investment represents a pivotal moment for Nous, providing the essential catalyst for its next major phase of growth and innovation. With the backing of key industry players, the company is now set to enhance the scientific validation of Koncentra while scaling its international operations. Nous's commitment to developing natural, clinically supported functional ingredients positions it strongly to lead within the rapidly evolving global wellness market.